Juan C. Osorio, Assistant Attending at Memorial Sloan Kettering Cancer Center and Director of Clinical Operations and Translational Immunology at The Rockefeller University, shared a post on LinkedIn by Lucas Blanchard, Postdoctoral Research Fellow in the lab of Jeffrey Ravetch The Rockefeller University, adding:
“Excited to share our recent review on therapeutic targeting of myeloid cells for cancer immunotherapy!
We discuss recent developments on myeloid targeting therapies, highlighting emerging mechanisms, translational insights, and key challenges and opportunities for clinical implementation. Outstanding work by rockstar postdoc Lucas Blanchard on leading this effort, also huge thanks to Andrew Mijačika for his contribution on putting this review together.”
Quoting Lucas Blanchard‘s post:
“PAPER ALERT: Our review on the targeting of myeloid cells for cancer immunotherapy is out in CIR AACR Journals
Cancer immunotherapies manipulating T lymphocytes, such as immune checkpoint blockade, have shown remarkable clinical success. However, these treatments benefit only to a minority of patients, highlighting the need for novel strategies targeting other cell populations and molecular pathways. Here, we discuss myeloid cell-targeting immunotherapies, focusing on antibody-based approaches that have reached the clinic.
I was really glad to write this review with talented student Andrew Mijačika and young PI Juan C. Osorio.
By the way, if you are currently looking for a postdoc, I strongly recommend you to contact Juan C. Osorio. He is an amazing scientist, clinician and mentor, whose new lab will investigate exciting and important research topics in cancer immunology and immunotherapy !”
Title: Targeting Myeloid Cells for Cancer Immunotherapy
Authors: Lucas Blanchard, Andrew Mijacika, Juan C. Osorio
Read the full article on AACR Journal.
Read more posts featuring Juan C. Osorio on OncoDaily.